Format

Send to

Choose Destination
Br Med Bull. 2013;107:57-68. doi: 10.1093/bmb/ldt023. Epub 2013 Aug 16.

Immunization to prevent congenital cytomegalovirus infection.

Author information

1
Department of Microbiology, Medical College of Virginia Campus/Virginia Commonwealth University, PO Box 163, Richmond, VA 23298, USA. sadler@vcu.edu

Abstract

INTRODUCTION:

A primary maternal cytomegalovirus (CMV) during pregnancy causes newborn disease that includes hearing deficit and/or mental retardation.

SOURCES OF DATA:

Relevant published literature.

AREAS OF AGREEMENT:

There are no biologic obstacles to immunization against fetal/placental infection with CMV.

AREAS OF UNCERTAINTY:

CMV vaccine trials may be difficult due to a lack of public awareness of CMV. Vaccine trials that use fetal infection as an endpoint will be prolonged, since vaccination will need to occur preconception.

AREAS TIMELY FOR DEVELOPING RESEARCH:

Vaccines in preclinical development include antigens of the CMV gB glycoprotein and the gH/gL UL128, 130 and 131 pentameric complex. These antigens induce antibodies that block viral entry into fibroblasts and endothelial/epithelial cells. Vaccines immunogenic in animals include an inactivated virus with a wild-type UL131 gene, a DNA vaccine using a wild-type UL130 gene and peptide vaccines using peptides from UL130 and 131.

CONCLUSIONS:

In spite of these potential obstacles, successful evaluation of CMV vaccines is possible.

KEYWORDS:

cytomegalovirus; pregnancy; vaccines

PMID:
23954939
DOI:
10.1093/bmb/ldt023
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center